Anti-IL-5 therapies for chronic obstructive pulmonary disease

Author(s) Donovan T.; Milan S.J.; Wang R.; Banchoff E.; Bradley P. et al.
Source The Cochrane database of systematic reviews; Dec 2020; vol. 12
Language English
Publication Date Dec 2020
BACKGROUND: Exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of hospital admissions, disease-related morbidity and mortality. COPD is a heterogeneous disease with distinct inflammatory phenotypes, including eosinophilia, which may drive acute exacerbations in a subgroup of patients. Monoclonal antibodies targeting interleukin 5 (IL-5) or its receptor (IL-5R) have a role in the care of people with severe eosinophilic asthma, and may similarly provide therapeutic benefit for people with COPD of eosinophilic phenotype. 

• Available in full text at The Cochrane database of systematic reviews from Cochrane Collaboration (Wiley)